Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs

Blood

Volumn 92, Issue 1, 1998, Pages 259-266

  Kaspers, G J L ^a   Pieters, R ^b   Van Zantwijk, C H ^b   Van Wering, E R ^b   Van Der Does Van Den Berg, ^b   Veerman, A J R ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; MERCAPTOPURINE; MITOXANTRONE; PREDNISOLONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CROSS RESISTANCE; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; LC 50; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032126675     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.1.259.413k21_259_266     Document Type: Article

References (39)

1. Veerman AJP, Pieters R: Drug sensitivity assays in leukaemia and lymphoma. Br J Haematol 74:381, 1990
2. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MWJ, Heyenbrok MW, Hählen K, Veerman AJP: In vitro sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76:2327, 1990
3. Kaspers GJL, Kardos G, Pieters R, Van Zantwijk CH, Klum per E, Hählen K, De Waal FC, Van Wering ER, Veerman AJP: Different cellular drug resistance profiles in childhood lymphoblastic and nonlymphoblastic leukemia: A preliminary report. Leukemia 8:1224, 1994
4. Klumper E, Ossenkoppele GJ, Pieters R, Huismans DR, Loonen AH, Rottier MMA, Westra G, Veerman AJP: In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 93:903, 1996
5. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G: Die Corticosteroid-Abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der Akuten Lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Pädiatr 199:151, 1986
6. Schrappe M, Reiter A, Riehm H: Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 14:2403, 1996
7. Kaspers GJL, Pieters R, Veerman AJP, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A: In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90:2723, 1997
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47:553, 1981
9. Van Wering ER, Brederoo P, Van Staalduinen GJ, Van Der Meulen J, Van Der Linden-Schrever BEM, Van Dongen JJM: Contribution of electron microscopy to the classification of minimally differentiated acute leukemias in children. Recent Results Cancer Res 131:77, 1993
10. Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G: Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis. Haematol Blood Transf 30:139, 1987
11. Kaspers GJL, Pieters R, Van Zantwijk CH, De Waal FC, Van Wering ER, Veerman AJP: Is resistance to prednisolone in vitro related to the response to prednisolone at initial diagnosis in childhood acute lymphoblastic leukemia? A preliminary analysis, in Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (eds): Drug Resistance in Leukemia and Lymphoma. The Clinical Value of Laboratory Assays. Hanwood, Chur, Switzerland, 1993, p 321
12. Smets LA, Homan-Blok, Hart A, De Vaan G, Behrendt H, Hählen K, De Waal FC: Prognostic implication of hyperdiploidy as based on DNA flow cytometric measurement in childhood acute lymphocytic leukemia - A multicenter study. Leukemia 1:163, 1987
13. Kaspers GJL, Pieters R, Van Zantwijk CH, De Laat PAJM, De Waal FC, Van Wering ER, Veerman AJP: In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64:469, 1991
14. Pieters R, Huismans DR, Leyva A, Veerman AJP: Adaptation of the rapid automated tetrazolium dye based MTT assay for chemosensitivity testing in childhood leukemia. Cancer Lett 41:323, 1988
15. Kaspers GJL, Veerman AJP, Pieters R, Broekema GH, Huismans DR, Kazimier KM, Loonen AH, Van Zantwijk CH, Hählen K, Van Wering ER: Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methylthiazol-tetrazolium assay. Br J Cancer 70:1047, 1994
16. Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP: Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study. Blood 85:751, 1995
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
18. Cox DR: Regression models and life tabels. J R Stat Soc 34:187, 1972
19. Pieters R, Huismans DR, Loonen AH, Hählen K, Van Der Does-Van Den Berg A, Van Wering ER, Veerman AJP: Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338:399, 1991
20. Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP: Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leuk Lymphoma 19:407, 1995
21. Klumper E, Pieters R, Kaspers GJL, Loonen AH, Huismans DR, Van Zantwijk CH, Hählen K, Van Wering ER, Henze G, Veerman AJP: In vitro cellular drug resistance in children with relapsed and refractory acute lymphoblastic leukemia. Blood 86:3681, 1995
22. Klumper E, Pieters R, Kaspers GJL, Huismans DR, Loonen AH, Rottier MMA, Van Wering ER, Van Der Does-Van Den Berg A, Hählen K, Creutzig U, Veerman AJP: In vitro chemosensitivity testing in childhood acute non-lymphoblastic leukemia using the MTT assay. Leukemia 9:1864, 1995
23. Pieters R, Kaspers GJL, Van Wering ER, Huismans DR, Loonen AH, Hählen K, Veerman AJP: Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 7:392, 1993
24. Kaspers GJL, Pieters R, Klumper E, De Waal FC, Veerman AJP: Glucocorticoid resistance in childhood leukemia - A review. Leuk Lymphoma 13:187, 1994
25. Pieters R, Klumper E, Kaspers GJL, Veerman AJP: Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. A review. Crit Rev Oncol Hematol 25:11, 1997
26. Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk I, Hählen K, Van Wering ER: Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 19:175, 1995
27. Bleyer WA, Dedrick RL: Clinical pharmacology of intrathecal methotrexate: I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61:703, 1977
28. Jacobs SA, Bleyer WA, Chabner BA, Johns DG: Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet 1:465, 1975
29. Simmons ED, Somberg KA: Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 67:2062, 1991
30. Thyss A, Suciu S, Bertrand Y, Maringue F, Robert A, Vilmer E, Mechinaud F, Benoit Y, Brock P, Ferster A, Lutz P, Boutard P, Marguerite G, Plouvier E, Michel G, Plantaz D, Munzer M, Riallard X, Chantraine JM, Norton L, Solbu G, Philippe N, Otten J: Systemic effect of intrathecal metholrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 15:1824, 1997
31. Baxter JD, Forsham PH: Tissue effects of glucocorticoids. Am J Med 53:573, 1972
32. Den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJP: Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein (P-gp) expression and drug resistance in childhood leukemia. Blood 91:2092, 1998
33. Cline MJ, Rosenbaum E: Prediction of in vivo cytotoxicity of chemotherapeutic agents by their in vitro effect on leukocytes from patients with acute leukemia. Cancer Res 28:2516, 1968
34. Lippman ME, Konior G, Leventhal BG: Clinical implications of glucocorticoid receptors in human leukemia. Cancer Res 38:4251, 1978
35. Nanni P, Nicoletti G, Prodi G, Galli MC, De Giovanni C, Grilli S, Lollini P-L, Gobbi M, Cavo M, Tura S: Glucocorticoid receptor and in vitro sensitivity to steroid hormones in human lymphoproliferative diseases and myeloid leukemia. Cancer 49:623, 1982
36. Ho AD, Hunstein W, Ganeshaguru K, Hoffbrand AV, Brandeis WE, Denk B: Therapeutic and prognostic implications of glucocorticoid receptors and terminal deoxynucleotidyl transferase in acute leukemia. Leuk Res 6:1, 1982
37. Homo F, Duval D, Harousseau JL, Marie J-P, Zittoun R: Heterogeneity of the in vitro responses to glucocorticoids in acute leukemia. Cancer Res 40:2601, 1980
38. Mastrangelo R, Malandrino R, Riccardi R, Longo P, Ranelletti FO, Iacobelli S: Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia. Blood 56:1036, 1980
39. Goldie JH, Coldman AJ: The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 44:3643, 1984